Good news to see positive operating cash flows.
Significant costs in R&D and staff costs but that is expected. R&D will be laced with tax incentives so it good to look at it as a NIL expense, and continued government funding will continue to drive the R&D.
Net $195k outflows for an entire quarter is a great result, especially for a company in its infancy stages.
Hopefully operating cash flows can stay positive, especially with the addition of the I-med contracts going forward.
GLTAH.
Ann: Quarterly Activity Report and Appendix 4C for Q3 FY2022, page-2
Add 4DX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $180.6M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 44.5¢ | 43.5¢ | $46.87K | 106.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1782 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 78422 | 10 |
View Market Depth
| Last trade - 11.03am 02/09/2024 (20 minute delay) ? |
| 4DX (ASX) Chart |